Chengzhi Zhou

5PUBLICATIONS
12CO-AUTHORS
Molecular targetsPredictive and prognostic markersGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jan 06, 2025
Selpercatinib in Chinese patients with RET-fusion-positive non-small-cell lung cancer: updated efficacy and safety analysis from the LIBRETTO-321 phase II trial.

Shun Lu, Ying Cheng, Dingzhi Huang

|Aug 07, 2024
Pretreatment pulmonary tumor necrosis is a promising prognostic imaging biomarker for first-line anti-PD-1/PD-L1 therapy in advanced lung squamous cell carcinoma: a multi-institutional, propensity score-matching cohort analysis.

Qiaofeng Zhong, Longfeng Zhang, Lin Wu

|Aug 02, 2024
A pooled analysis of clinical outcome in driver-gene negative non-small cell lung cancer patients with MET overexpression treated with gumarontinib.

Yongfeng Yu, Wen Dong, Yanxia Shi

|Oct 24, 2022
First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis.

Chongxiang Chen, Chunning Zhang, Huaming Lin

|Aug 04, 2022
Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321).

Shun Lu, Ying Cheng, Dingzhi Huang

Pageof 1

Frequent Collaborators

3 joint publications

Shun Lu

3 joint publications

Dingzhi Huang

1 joint publications

Chongxiang Chen

1 joint publications

Xiaotao Zhang